IQVIA Holdings Inc.

IQVIA Holdings Inc.

IQV

$262.59

Updated: 04/11/2026, 11:40:40

Market Cap
$43.27B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US

No historical data available

Company Profile

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

USD
NYSE
CEO: Ari Bousbib
Employees: 94,000
https://www.iqvia.com
Asset Summaries
Latest generated summaries for IQV

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
IQV-10-k-fy2025.html3.1 MBtext/htmlENFiled 17/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 40 KPI observations

Revenue

$16.3B

FY 2025 · Reported

Net income

$1.4B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

N/A

FY — · Reported

R&D intensity

N/A

FY — · Reported

Share repurchases

$1.2B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Service-based revenue model
Healthcare-grade AI and AI governance

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Global provider of clinical research services, commercial insights and healthcare intelligence; ~93,000 employees in over 100 countries

98%
Source evidence
“IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries.”

R&D Solutions contract termination terms

Most R&D Solutions clients can terminate contracts upon 30 to 90 days' notice; terminations are a regular part of the business

98%
Source evidence
“Most of our Research & Development Solutions clients can terminate our contracts upon 30 to 90 days' notice.”

Company overview

Global clinical research services and healthcare intelligence provider; ~93,000 employees in over 100 countries

98%
Source evidence
“IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. ... With approximately 93,000 employees in over 100 countries”

Three reportable segments

Technology & Analytics Solutions; Research & Development Solutions; Contract Sales & Medical Solutions

98%
Source evidence
“We are managed through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions.”

Workforce composition by service line (three reported solutions segments)

Three service lines: TAS, R&DS, CSMS (employee counts disclosed per line)

90%
Source evidence
“including over 31,000 Technology & Analytics Solutions employees, approximately 51,000 Research & Development Solutions employees and approximately 7,000 Contract Sales & Medical Solutions employees”

Customer base

Biotech, pharma and medical device companies, researchers, government agencies, payers

94%
Source evidence
“Our insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders”

Service-based revenue model

No material product revenues; revenues from provision of services

95%
Source evidence
“Total revenues are comprised of revenues from the provision of our services. We do not have any material product revenues.”

Healthcare-grade AI and AI governance

Healthcare-grade AI® with ML, NLP, generative and agentic AI; governed under Defensible/Trustworthy/Responsible AI principles

93%
Source evidence
“IQVIA has a rich history of developing Healthcare-grade AI®. We have steadily expanded our capabilities over the years in connection with machine learning, natural language processing and generative and agentic AI”

Non-USD revenue share

Approximately 30% of 2025 revenues denominated in currencies other than USD (~60 currencies)

97%
Source evidence
“approximately 30% of our revenues were denominated in currencies other than the United States dollar, which represents approximately 60 currencies”

2025 constant currency revenue growth by segment

Revenues $16,310M (+5.9%); constant currency +$737M (4.8%): TAS +$380M, RDS +$298M, CSMS +$59M

95%
Source evidence
“constant currency revenue growth of approximately $737 million, or 4.8%, reflecting a $380 million increase in Technology & Analytics Solutions, a $298 million increase in Research & Development Solutions, and a $59 million increase in Contract Sales & Medical Solutions.”

Operations and dependencies

Data supplier network

~150,000 data suppliers providing over one million data feeds

95%
Source evidence
“sourced from approximately 150,000 data suppliers and covering over one million data feeds globally”

Third-party data suppliers for Commercial Solutions

Commercial Solutions depends on numerous third-party data suppliers; collective restrictions could materially adversely impact services

96%
Source evidence
“Our Commercial Solutions information services are derived from data we collect from third parties.”

Third-party support services dependency

Depends on third parties for transportation, clinical trial drugs, lab kits, reagents, and equipment maintenance

95%
Source evidence
“third- party transportation providers, suppliers of drugs for patients participating in clinical trials, suppliers of kits for use in our clinical trial laboratories business, suppliers of reagents for use in our testing equipment and providers of maintenance contracts for our equipment”

Employee count and segment breakdown

~93,000 employees in 100+ countries: >31,000 TAS, ~51,000 R&DS, ~7,000 CSMS

97%
Source evidence
“A staff of approximately 93,000 employees across the globe, including over 31,000 Technology & Analytics Solutions employees, approximately 51,000 Research & Development Solutions employees and approximately 7,000 Contract Sales & Medical Solutions employees.”

Positioning and strategy

Connected Intelligence capabilities

IQVIA Connected Intelligence: healthcare-specific IT infrastructure, analytics-driven clinical development, real-world ecosystem, proprietary applications

92%
Source evidence
“Integration of information, analytics, technology, and domain expertise through IQVIA Connected Intelligence”

Growth and innovation in life sciences industry

Life sciences ~$1.94T revenues 2025; emerging markets pharma spend 5-8% CAGR through 2030; ~375 NMEs expected 2026-2030

94%
Source evidence
“estimated to have generated approximately $1.94 trillion in revenues in 2025”

Key demand trends

Six key trends driving demand: life sciences growth, R&D growth/patent cliff, R&D complexity, client efficiency pressures, data integration needs

92%
Source evidence
“We believe there are six key trends affecting our end markets that will create increasing demand for research and development services, technology & analytics solutions and contract sales and medical solutions”

Total addressable market ~$335 billion

~$335B market: $75B outsourced R&D, $90B RWE/connected health, $84B tech-enabled commercial ops

95%
Source evidence
“We compete in a market of approximately $335 billion consisting of outsourced research and development, real-world evidence and connected health and technology enabled clinical and commercial operations markets”

Risks, financing, and outlook

Cost of revenues trend

Cost of revenues rose 8.5% to $10,880M; 66.7% of revenues vs 65.1% in 2024

94%
Source evidence
“cost of revenues, exclusive of depreciation and amortization, increased $850 million in 2025, or 8.5%”

Restructuring costs

Restructuring costs $105M in 2025 (vs $67M 2024, $84M 2023); actions expected through 2026

93%
Source evidence
“The restructuring costs incurred were due to ongoing efforts to streamline our global operations and reduce overcapacity... These restructuring actions are expected to occur throughout 2026”

Liquidity and revolver position

Cash $1,980M; $800M drawn under $2,000M revolving credit facility as of Dec 31, 2025

97%
Source evidence
“cash and cash equivalents were $1,980 million and we had $800 million drawn under our $2,000 million revolving credit facility”

Interest expense increase

Interest expense $729M in 2025, up from $670M, due to higher outstanding debt balances

95%
Source evidence
“Interest expense during 2025 increased compared to 2024 as a result of higher outstanding debt balances.”

Indebtedness restrictions and interest rate exposure

Senior Secured Credit Facilities and IQVIA Inc. note indentures impose restrictions; interest rate fluctuations may affect results

90%
Source evidence
“Restrictions imposed in the Senior Secured Credit Facilities (as defined below) and other outstanding indebtedness, including the indentures governing outstanding notes issued by our wholly owned subsidiary IQVIA Inc.”

Emerging markets and local clinical trial requirements

Local-population trial requirements in Asian/emerging markets; IQVIA cites unmatched Asia presence as strength

90%
Source evidence
“Regulators require clinical trials to involve local populations as part of the process for approving new pharmaceutical products, especially in certain Asian and emerging markets.”

Segment reporting change effective January 1, 2026

Effective Jan 1, 2026, CSMS merges into Commercial Solutions; Real-World Late Phase moves to R&D Solutions

95%
Source evidence
“Effective January 1, 2026, we will be updating our segment reporting... the Contract Sales & Medical Solutions segment... will be incorporated into the Technology & Analytics Solutions segment, which is renamed Commercial Solutions.”

Clinical trial regulatory compliance requirements

Must comply with FDA, EMA, EU competent authorities, MHRA requirements and GLP/GCP; DEA rules for controlled substances; failures could bring sanctions, penalties, or personal injury claims

95%
Source evidence
“we must adhere to applicable regulatory requirements such as those required by the FDA, the EMA and the competent authorities of the member states of the EU, and the MHRA in the UK”

Emerging AI regulation

Compliance with emerging AI regulation: EU AI Act and Colorado AI Act

95%
Source evidence
“supports our compliance with existing laws (e.g., clinical, employment, intellectual property, consumer protection, competition) and emerging AI regulation such as the European Union’s Artificial Intelligence Act (the "EU AI Act") and the Colorado AI Act.”

Data privacy and laboratory regulation

Subject to global data privacy laws and lab regulations (DEA, CLIA, OSHA, IATA, EPA)

93%
Source evidence
“laboratories that analyze human blood or other biological samples for the diagnosis and treatment of clinical trial subjects must comply with Clinical Laboratory Improvement Amendments ("CLIA")”

Contract loss/delay risk

Loss or delay of large contracts or multiple contracts could adversely affect revenues and profitability; termination fees may not cover anticipated revenues or profits

97%
Source evidence
“the loss or delay of a large contract or the loss or delay of multiple contracts could adversely affect our revenues and profitability”

Client/therapeutic concentration and conflicts

Client consolidation, therapeutic concentration, and serving competing biopharmaceutical clients may adversely affect service usage; IQVIA may fund trial wind-downs at its own expense

93%
Source evidence
“we may initiate a clinical trial for a client, and then the client becomes unwilling or unable to fund the completion of the clinical trial, and we may be ethically bound to complete or wind down the clinical trial at our own expense”

Industry competition

Biopharmaceutical services industry is highly competitive; competes with other service companies and clients' internal departments

92%
Source evidence
“The biopharmaceutical services industry is highly competitive. Our business often competes with other biopharmaceutical services companies, internal discovery departments, development departments, sales and marketing departments, information technology departments”

Liability exposure from R&D and Contract Sales services

R&D Solutions and Contract Sales & Medical Solutions could create liability if drugs harm patients; insurance may not cover all indemnification obligations

92%
Source evidence
“Our Contract Sales & Medical Solutions business could result in liability to us if a drug causes harm to a patient.”

Demand sensitivity to biopharmaceutical R&D budgets

Outsourcing trends, changes in aggregate R&D spending and budgets, healthcare reform, and drug withdrawal/scope-limiting actions could adversely affect results

90%
Source evidence
“Outsourcing trends in the biopharmaceutical industry and changes in aggregate spending and research and development budgets could adversely affect our operating results and growth rate.”

Workforce/talent risk

Significant competition for qualified personnel, especially AI/ML and clinical specialties; immigration restrictions and wage inflation could raise costs

90%
Source evidence
“There is significant and increasing competition for qualified personnel, particularly those with higher educational degrees, such as a medical degree, a Ph.D. or an equivalent degree, cutting-edge skillsets, such as AI and machine learning”

Client cost pressure driving outsourcing demand

Client margin pressure and specialty-product shift push outsourcing and efficiency demand

90%
Source evidence
“we believe our clients will face increased operating margin pressure due to their changing product mix, pricing and reimbursement challenges, and rising costs of compliance.”

Credit/capital market disruption affecting clients

Credit and capital market disruptions could impair clients' ability to pay; past instances of cancellations and late payment tied to client financing difficulty

88%
Source evidence
“a limited number of instances in our Research & Development Solutions business during the past several years where cancellations, changes in scope and failure to pay timely were attributable, at least in part, to difficulty in our clients' ability to obtain financing”

Material exposure graph

Healthcare / biopharmaceutical clients
Revenue Exposure

R&D budgets, outsourcing trends, and healthcare reform at biopharmaceutical clients drive demand for IQVIA's services.

Relevance 95·Dependency 92·Confidence 92
Source evidence
“Outsourcing trends in the biopharmaceutical industry and changes in aggregate spending and research and development budgets could adversely affect our operating results and growth rate.”
Life sciences companies (biopharma, biotech, medical device)
Customer Exposure

Revenue depends on biotech, medical device and pharmaceutical companies as principal clients across R&D and commercialization value chain.

Relevance 95·Dependency 85·Confidence 94
Source evidence
“Our insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders”
Global biopharmaceutical companies
Customer Exposure

Broader partnering arrangements with global biopharmaceutical companies amplify the impact of multi-contract loss or delay.

Relevance 92·Dependency 90·Confidence 90
Source evidence
“We believe the risk of loss or delay of multiple contracts potentially has greater effect where we are party to broader partnering arrangements with global biopharmaceutical companies.”
Clinical trial regulations (FDA/EMA/MHRA, GLP/GCP, DEA)
Regulatory Exposure

Clinical development services must comply with FDA, EMA, MHRA, GLP/GCP and DEA requirements; non-compliance could bring sanctions, penalties, and liability.

Relevance 90·Dependency 85·Confidence 93
Source evidence
“we must adhere to applicable regulatory requirements such as those required by the FDA, the EMA and the competent authorities of the member states of the EU, and the MHRA in the UK”
Data suppliers (~150,000)
Supplier Dependency

IQVIA's data assets—core to its intelligence offerings—are sourced from approximately 150,000 data suppliers across more than one million data feeds.

Relevance 90·Dependency 75·Confidence 92
Source evidence
“approximately 68 petabytes of unique proprietary data sourced from approximately 150,000 data suppliers and covering over one million data feeds globally”
Third-party data
Supplier Dependency

Commercial Solutions offerings are derived from third-party data; supplier restrictions or refusals could impair services and results.

Relevance 85·Dependency 85·Confidence 90
Source evidence
“Our Commercial Solutions information services are derived from data we collect from third parties.”
Artificial Intelligence
Demand Driver

Healthcare-grade AI powers IQVIA's offerings and increases clinical trial efficiency from trial design to data submission; subject to emerging AI regulation.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“AI can be used to generate new insights and recommendations, helping to increase clinical trials efficiency at all stages from trial design to data submission.”
Healthcare-grade AI®
Technology Dependency

IQVIA's portfolio is powered by Healthcare-grade AI® trained on its proprietary health data, a key differentiator in clinical development and analytics offerings.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“IQVIA Healthcare-grade AI® supports our AI-powered offerings, engineered to meet the level of precision, speed, and trust needed by the industry.”
Biopharmaceutical services industry competition
Competitive Exposure

Highly competitive industry including larger biopharmaceutical services companies and clients' internal departments; failure to adapt to technological change could materially impact the business.

Relevance 80·Dependency 75·Confidence 90
Source evidence
“The biopharmaceutical services industry is highly competitive and our business could be materially impacted if we do not compete effectively or rapidly adapt to technological change.”
Patent cliff and R&D growth
Demand Driver

Major biopharma efforts to replenish patent-cliff revenue losses and higher NME approval rates drive R&D spending and outsourcing demand.

Relevance 80·Dependency 60·Confidence 88
Source evidence
“major biopharmaceutical companies’ efforts to replenish revenues lost from the so-called "patent cliff," increased access to capital by the small and midcap biotechnology industry”
United States dollar
Currency Exposure

~30% of revenues in ~60 non-USD currencies create translation exposure on consolidated USD-reported results

Relevance 78·Dependency 70·Confidence 95
Source evidence
“Because a large portion of our revenues and expenses are denominated in foreign currencies and our financial statements are reported in United States dollars, changes in foreign currency exchange rates can significantly affect our results of operations.”
Clinical trial supplies (drugs, kits, reagents)
Raw Material Dependency

Third-party drugs, kits, reagents and maintenance providers are critical support services whose failure would materially harm the business.

Relevance 75·Dependency 78·Confidence 88
Source evidence
“The failure of any of these third parties to adequately provide the critical support services could have a material adverse effect on our business.”
AI (Healthcare-grade AI)
Revenue Exposure

Portfolio solutions powered by Connected Intelligence and Healthcare-grade AI; commitment to responsible AI with privacy, regulatory compliance and patient safety

Relevance 75·Dependency 60·Confidence 90
Source evidence
“IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics”
Skilled labor competition
Cost Driver

Competition for AI/ML, clinical, and technical talent, inflation, and immigration restrictions could raise wage costs and impair hiring/retention.

Relevance 72·Dependency 70·Confidence 88
Source evidence
“Increases in inflation, competition and shortages of qualified personnel in certain specialty areas may make it more difficult to hire and retain our key employees and could result in substantial increased costs, such as increased wage rates”
Health data and analytics technology
Technology Dependency

Technology & Analytics Solutions provides mission critical information, technology solutions and real world insights; data acquisition/processing is a cost component

Relevance 72·Dependency 65·Confidence 85
Source evidence
“Technology & Analytics Solutions provides mission critical information, technology solutions and real world insights and services to our life science clients.”
Payments to clinical trial investigators
Cost Driver

Reimbursed expenses comprised principally of investigator payments and travel are a principal cost component

Relevance 70·Dependency 65·Confidence 90
Source evidence
“Reimbursed expenses, which are included in cost of revenues, are comprised principally of payments to investigators who oversee clinical trials and travel expenses for our clinical monitors and sales representatives.”
Credit and capital market conditions
Revenue Exposure

Client financing difficulties have caused cancellations, scope changes, and late payments in R&D Solutions; credit disruptions also affect interest expense on floating-rate-type debt.

Relevance 68·Dependency 62·Confidence 85
Source evidence
“cancellations, changes in scope and failure to pay timely were attributable, at least in part, to difficulty in our clients' ability to obtain financing”
Emerging markets life sciences growth
Demand Driver

Emerging market pharmaceutical spending expected to grow at 5-8% CAGR through 2030, driving demand for localized data and clinical development capabilities.

Relevance 65·Dependency 45·Confidence 87
Source evidence
“spending on pharmaceuticals in emerging markets will expand at a 5% to 8% compound annual growth rate (“CAGR”) through 2030”
Interest rates / debt balances
Cost Driver

Interest expense rose to $729M in 2025 on higher debt balances; interest income fell on lower deposit rates

Relevance 62·Dependency 60·Confidence 90
Source evidence
“Interest expense during 2025 increased compared to 2024 as a result of higher outstanding debt balances.”
Workforce/restructuring overcapacity
Cost Driver

Restructuring to reduce overcapacity and consolidate functions continuing through 2026

Relevance 60·Dependency 55·Confidence 85
Source evidence
“ongoing efforts to streamline our global operations and reduce overcapacity to adapt to changing market conditions and integrate acquisitions”
EU AI Act
Regulatory Exposure

IQVIA's AI-powered offerings must comply with the EU AI Act and Colorado AI Act, with policies for higher-risk and lower-risk AI activities.

Relevance 60·Dependency 40·Confidence 93
Source evidence
“supports our compliance with existing laws ... and emerging AI regulation such as the European Union’s Artificial Intelligence Act (the "EU AI Act") and the Colorado AI Act.”
Healthcare regulatory compliance
Cost Driver

Rising compliance costs at clients push outsourcing demand, while IQVIA itself bears compliance costs across privacy, laboratory and clinical regulations.

Relevance 60·Dependency 40·Confidence 85
Source evidence
“Despite expected accelerating growth in the global life sciences market, we believe our clients will face increased operating margin pressure due to their changing product mix, pricing and reimbursement challenges, and rising costs of compliance.”
Full company information
Latest profile, trading, valuation, and identifier data stored for IQV.
Share price
$262.59
Market cap
$43.27B
Exchange
NYSE
Currency
USD
CEO
Ari Bousbib
Employees
94,000
IPO date
09/05/2013
Beta
1.164
Last dividend
$0.00
Day range
$253.63 – $263.99
52-week range
$154.50 – $284.50
1-day performance
1.61%
1-year performance
69.96%
Current drawdown (1Y)
-7.70%
CIK
0001478242
CUSIP
46266C105
ISIN
US46266C1053
Created
07/12/2025, 04:45:46
Last update
04/11/2026, 11:40:40

Track IQVIA Holdings Inc. with an AI analyst

See which prediction-market events move IQV, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.